Pediatric Low-Dose Ketamine: Dosing Considerations and Safety

Pediatric low-dose ketamine dosing considerations and safety require specialist assessment because children are not simply smaller adults. Published psychiatric studies are small, most involve adolescents, and they do not establish a standard outpatient dose or schedule for younger children. Families considering ketamine should ask how the clinician will assess diagnosis, monitor acute effects, track function and cognition, and decide whether further treatment is justified.

Ketamine has a long history in pediatric anesthesia and procedural sedation, but that experience does not answer every question about repeated sub-anesthetic treatment for depression, suicidal thoughts, or chronic pain. Developmental changes in metabolism, body composition, and brain maturation can affect exposure and risk.

Why age changes ketamine dosing decisions

Age can change how quickly ketamine is cleared and how a weight-based dose translates into blood levels. Drug-metabolizing enzymes mature across infancy and childhood, so the same mg/kg dose may not produce the same exposure in a neonate, young child, adolescent, and adult. A review of pediatric pharmacokinetics describes how growth and maturation can alter drug clearance and distribution across childhood. Read the pharmacokinetics review on PubMed.

That is why a published adolescent research regimen should not be treated as a dosing instruction for a younger child. In one small open-label study, 13 adolescents with treatment-resistant depression received six intravenous infusions of 0.5 mg/kg over 40 minutes. The study reported improvement for some participants, but its size and design cannot determine the best dose, interval, or long-term safety profile for pediatric patients.

What the current evidence can and cannot answer

Early reports and small studies have examined ketamine in adolescents with treatment-resistant depression, acute suicidality, and pediatric pain conditions. They suggest potential short-term benefit for some patients, but they leave important questions about comparative effectiveness, durability, repeated exposure, and long-term cognitive outcomes.

According to the FDA-approved prescribing information, SPRAVATO, an esketamine nasal spray, is indicated for adults with treatment-resistant depression and certain adults with depressive symptoms in acute suicidal ideation or behavior. The label does not establish pediatric psychiatric use. See the FDA prescribing information for SPRAVATO.

For acute safety context, pediatric procedural sedation literature is relevant but not interchangeable with psychiatric treatment. Sedation can involve different doses, settings, goals, and observation procedures. Families should not infer that a medication's use in a monitored procedure automatically supports a repeated mental-health protocol.

Safety monitoring to discuss before treatment

A pediatric plan should define what will be measured before, during, and after each treatment. Acute monitoring may include blood pressure, heart rate, oxygenation when clinically appropriate, dissociation, agitation, nausea, and recovery before discharge. The plan should also identify who can respond if symptoms worsen between visits.

Longer-term follow-up matters because cognitive and developmental effects after repeated sub-anesthetic exposure remain uncertain. Ask whether the care team will document school functioning, sleep, mood symptoms, suicidal thoughts when relevant, medication changes, and attention or memory concerns. For a broader view of treatment-related adverse effects, see common ketamine side effects and cardiovascular monitoring.

Questions parents and guardians can take to the clinical team

Consent, assent, and treatment spacing

For pediatric psychiatric use, a careful consent discussion should distinguish what is known from what remains uncertain. Parents or guardians should have an opportunity to review alternatives, foreseeable acute effects, limits of the evidence, and the proposed follow-up plan. When developmentally appropriate, the young person should also be included through assent.

No consensus schedule exists for pediatric sub-anesthetic ketamine. A conservative plan should explain the reason for each treatment, use symptom and function tracking rather than assuming more treatments are better, and reassess after each phase. Read how low-dose ketamine treatments may be spaced for questions to bring to a scheduling discussion, and how many ketamine treatments may be needed for the limits of standard treatment-count assumptions.

The practical takeaway is straightforward: pediatric ketamine decisions need an age-specific, closely monitored plan, not a copied adult protocol. The strongest unanswered questions concern long-term outcomes, repeated exposure, and which young patients are most likely to benefit.